About Lantheus
Lantheus is a publicly listed company based in Billerica (United States) founded in 2008. The company has 808 employees. Lantheus has completed 5 acquisitions, including Cerveau Technologies, Evergreen Theragnostics and Life Molecular Imaging. Its website lantheus.com draws about 24 thousand monthly visits. Lantheus offers products and services including PYLARIFY, AZEDRA, DEFINITY, and LUMINITY. Its focus areas include Life Sciences, Imaging Diagnostics, Diversified and HealthTech. Its competitors include AIdoc, SOFIE and Cleerly; 3 of its 3 listed competitors have raised funding.
Company details
Developer of diagnostic imaging agents and targeted therapeutics. The companys lead candidate is PNT2002 a small molecule PSMA-targeted 177Lu-based radioligand therapy for metastatic castration-resistant prostate cancer. It also offers software like DEFINITY, VIALMIX, PINSYNC, TechneLite, and more. It offers imaging agents that assist in the diagnosis of heart and vascular diseases with nuclear imaging, echocardiography, and magnetic resonance imaging (MRI) technologies.
- Headquarters Billerica, United States
- Employees 808
- Stage Public
- SectorsHealthcare
- Website lantheus.com
- Social LinkedIn X Facebook
- Legal Name Lantheus Holdings, Inc.
- Annual Revenue$1.54 B (USD)0.5as on Dec 31, 2025
- Net Profit$233.56 M (USD)-25.25as on Dec 31, 2025
- EBITDA$382.31 M (USD)-25.11as on Dec 31, 2025
- Latest Funding Round$300K (USD), Grant
Jun 2012
- Investors
- Employee Count808
- Investments & AcquisitionsCerveau Technologies
& 4 more
Products & Services of Lantheus
Lantheus offers a comprehensive portfolio of products and services, including PYLARIFY, AZEDRA, DEFINITY, and LUMINITY.
Radiopharmaceutical for detecting prostate cancer in patients.
Treatment for certain neuroendocrine tumors.
Ultrasound contrast agent for cardiac imaging.
Contrast agent for ultrasound procedures.
Funding Insights of Lantheus
- Total Rounds 2
- Last Round Grant — $300,000
- First Round $2.25M
(Apr 2011)
- Investors Count 1
All 2 funding rounds of Lantheus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2012 | $300,000 | Grant | – | – | – |
| Apr 2011 | $2.25M | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Lantheus
Lantheus has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Lantheus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Lantheus
230 people are tracked at Lantheus (126 in leadership, 8 in board & advisors, 96 in team); the tracked headcount is 808.
| Name | Role | Group |
|---|---|---|
Jean-Claude Provost | Chief Science Officer | Leadership |
Seshagiri Gopi | Director Of IT | Leadership |
Mary Anne Hein | President & CEO | Leadership |
Joann Nestor | Senior Vice President, Legal Affairs | Leadership |
Lawrence Cogswell | Executive Director, IP Asset Strategy | Leadership |
Christine S. | Director, Customer Experience, PET Channel Management | Leadership |
Michael Ferencsik | Director, IT - Commercial | Leadership |
Carson Burrington | Associate Director, Talent Acquisition | Leadership |
Meghan Strouss | Executive Director, Head Of External Manufacturing | Leadership |
Jamie Spaeth | Chief People Officer | Leadership |
Bob Maluso | Head Of PET Manufacturing Facility (pmf) Strategy | Leadership |
Jacob Bourgeois | Sr. Director Of Manufacturing Engineering | Leadership |
Holly Irvine | Director, Enterprise Project Management (epmo) | Leadership |
Junfang June Li | Vice President Of Biometrics & Data Sciences | Leadership |
David Dentino | Director IT - Quality Systems | Leadership |
Lindsye Mitchell | Senior Director Of Marketing | Leadership |
Robert J. Marshall Jr. | CFO & Treasurer | Leadership |
James S. | Vice President, Infrastructure And Operations | Leadership |
Mark Jastive | Senior Director Sales Operations | Leadership |
Karen Stewich | Sr. Director Commercial Information Management | Leadership |
210 more people are available in the full profile.
Complete people profiles for Lantheus
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Lantheus
Lantheus is a publicly listed company on the NASDAQ with ticker symbol LNTH in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Jun 2015
- Listed onNASDAQ: LNTH
- Listed entityLantheus Holdings, Inc.
- Exchange sectorHealth technology
- ISINUS5165441032
- Share price$100.02 (-0.09% on the day) · 2026-10-13
- Market capitalisation$6.53B
- Price to earnings24.2
- EPS (diluted, trailing year)$4.14
- Volume (last session)1,536,472
Financials of Lantheus
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.54B | $233.6M | $382.3M |
| 2024 | $1.53B | $312.4M | $510.5M |
| 2023 | $1.30B | $326.7M | $553.5M |
| 2022 | $935.1M | $28.1M | $118.8M |
| 2021 | $425.2M | -$71.3M | $38.6M |
Detailed financial statements for Lantheus
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lantheus
Lantheus has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Cerveau Technologies, Evergreen Theragnostics and Life Molecular Imaging.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Radiopharmaceutical manufacturing and regulatory services are provided. | evergreentgn.com | Jersey, United States | 2019 | Jan 2025 | $250M | |
PET tracers for neurodegenerative and cardiovascular diagnostics are developed. | life-mi.com | Berlingerode, Germany | 2012 | Jan 2025 | $350M | |
Provider of biomarkers and therapeutics development services | meilleurtechnologies.com | 2018 | Jul 2024 | •••• | ||
Research collaborations and global strategies are employed for product development. | cerveautechnologies.com | Boston, United States | 2015 | Feb 2023 | •••• | |
Imaging compounds & targeted radiotherapies to detect and treat prostate cancer. | progenics.com | United States | 1988 | Oct 2019 | •••• |
Complete acquisition details for Lantheus
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Lantheus
9 dated milestones of Lantheus across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Lantheus is founded.
- Funding First funding round of $2.3M.
- Funding Latest funding round, Grant, of $300K.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Progenics.
- Acquisition Acquires Cerveau Technologies.
- Acquisition Acquires Meilleur Technologies.
- Acquisition Acquires Life Molecular Imaging.
- Acquisition Acquires Evergreen Theragnostics.
Competitors of Lantheus
Lantheus has 3 listed competitors in our database, 3 of them funded. They include AIdoc, SOFIE and Cleerly.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aidoc.com | 2016 | New York, United States | $424.5M | AI-based single-screen system is provided to streamline medical imaging. | ||
| sofie.com | 2008 | Culver, United States | $43.1M | 546 | Developer of molecular imaging systems and radio-pharmaceuticals | |
| cleerlyhealth.com | 2016 | Denver, United States | $578.48M | Atherosclerotic plaque is quantified by AI using coronary CT angiograms. |
Detailed competitors of Lantheus
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Lantheus
The website of Lantheus (lantheus.com) receives about 23.6K visits a month.
- Monthly visits23.6K
Websites whose visitors overlap most with Lantheus. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| welchallyn.com | 100% | #6,683,118 | View details | ||
| iba-radiopharmasolutions.com | 100% | #3,532,970 | View details | ||
| nextgen.com | 99% | 3.1M | #17,633 | View details | |
| bracco.com | 99% | 40.1K | #741,979 | View details | |
| provationmedical.com | 99% | 5.7K | #3,134,212 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for Lantheus
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Imaging Diagnostics
3 companies that operate in the same segment as Lantheus (Imaging Diagnostics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Handheld ultrasound devices are developed for whole-body medical imaging. | 2011 | Guilford, Connecticut, United States | USD 350 M | USD 97.61 M | 464 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 | ||
Ultrasound images are analyzed via AI-based software provided by Exo. | 2015 | Redwood City, California, United States | USD 463.39 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lantheus
Complete news archive for Lantheus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lantheus
Lantheus was founded in 2008 and raised its 1st funding round 3 years after it was founded.
Lantheus is headquartered in Billerica, United States. It is registered at Billerica, Massachusetts, United States.
Lantheus has 808 employees.
Annual revenue of Lantheus is $1.54B as on Dec 31, 2025.
Developer of diagnostic imaging agents and targeted therapeutics. The companys lead candidate is PNT2002 a small molecule PSMA-targeted 177Lu-based radioligand therapy for metastatic castration-resistant prostate cancer. It also offers software like DEFINITY, VIALMIX, PINSYNC, TechneLite, and more. It offers imaging agents that assist in the diagnosis of heart and vascular diseases with nuclear imaging, echocardiography, and magnetic resonance imaging (MRI) technologies.
Lantheus offers PYLARIFY, AZEDRA, DEFINITY, and LUMINITY.
Yes, Lantheus is publicly traded on NASDAQ under the ticker symbol LNTH.
Lantheus has made 5 acquisitions, including Cerveau Technologies, Evergreen Theragnostics, and Life Molecular Imaging.
Lantheus has 1 investor. Key investors include HHS.